Ondansetron in pregnancy and risk of adverse fetal outcomes.
about
Interventions for treating hyperemesis gravidarumInterventions for treating hyperemesis gravidarumDoxylamine succinate-pyridoxine hydrochloride (Diclegis) for the management of nausea and vomiting in pregnancy: an overviewTreatment of gynecological cancers diagnosed during pregnancy.Ondansetron and pregnancy: Understanding the data.Using insurance claims data to identify and estimate critical periods in pregnancy: An application to antidepressants.Efficacy of prophylactic intravenous ondansetron on the prevention of hypotension during cesarean delivery: a dose-dependent study.Efficacy and safety of ondansetron in preventing postanesthesia shivering: a meta-analysis of randomized controlled trials.Treatment of nausea in pregnancy: a cross-sectional multinational web-based study of pregnant women and new mothers.Maternal use of oral contraceptives and risk of birth defects in Denmark: prospective, nationwide cohort study.Treatment of Nausea and Vomiting in Pregnancy: Factors Associated with ED RevisitsChallenges in interventional radiology: the pregnant patientManagement of gastrointestinal and liver diseases during pregnancy.Ondansetron: a review of pharmacokinetics and clinical experience in postoperative nausea and vomiting.Management of gynecological cancers during pregnancy.Management and controversies of classical Hodgkin lymphoma in pregnancy.Antiemetic use among pregnant women in the United States: the escalating use of ondansetron.Management of Hematologic Malignancies: Special Considerations in Pregnant Women.Managing Migraine During Pregnancy and Lactation.Use of anticancer agents in gynecological oncology during pregnancy: a systematic review of maternal pharmacokinetics and transplacental transfer.Nausea and vomiting of pregnancy - What's new?Multidisciplinary Management of Breast Cancer During Pregnancy.Treatment options for hyperemesis gravidarum.Hyperemesis Gravidarum: A Review of Recent Literature.Treatment of nausea and vomiting during pregnancy -a cross-sectional study among 712 Norwegian women.Off-label use of ondansetron in pregnancy in Western Australia.Safety considerations surrounding use of treatment options for nausea and vomiting in pregnancy.Making fair comparisons in pregnancy medication safety studies: An overview of advanced methods for confounding control.Vomiting in pregnancy is associated with a higher risk of low birth weight: a cohort study.Biology, staging, and treatment of breast cancer during pregnancy: reassessing the evidences.Gastrointestinal diseases during pregnancy: what does the gastroenterologist need to know?Minimal effective weight-based dosing of ondansetron to reduce hypotension in cesarean section under spinal anesthesia: a randomized controlled superiority trial
P2860
Q24185771-085735E9-8810-4397-801D-6B8A82E6AC39Q24202401-82075C25-D595-462A-9F3C-6A2A26023841Q27022394-2E6E7E0E-D08B-4104-8416-164CDAE26BD2Q30249061-B7CF795B-AF05-4E80-B1B9-CE1D503EB617Q31121039-CB34190E-508E-44FA-B5E3-CE4484A35205Q31145022-2B91DAFE-ED1C-4321-A026-BBE23ADD263DQ35017111-30E0D223-CCEC-45CA-B301-128C66F762F8Q35109410-D897F8CF-757C-48B3-B669-8747E2FAAC36Q35858260-2FDC371B-A1D7-41DD-AA21-A2D7CD20984CQ35887292-7B6DB790-11CE-4A88-9866-6C325D7B3FB0Q37245617-9879EF6B-C5B0-4F2B-9CF9-8085E84CD246Q37329873-E5CC56F8-460F-4D3C-811F-B5D1F71CC2BBQ38178818-3026E39F-2278-4304-A6E0-E1D23D0953B0Q38182638-D15E36E2-ABC8-413E-9626-47F8CE66DAE7Q38262618-49FACC0B-3A86-46D2-8298-DB964E2608D9Q38356460-CE92AB4C-3656-4D03-8042-9A7972F75D8CQ38402567-34EB8B89-DAA1-4EC4-A577-59374CC08879Q38594889-119B79A2-0381-46AB-B8C1-CB6A0D6C5A03Q38784408-2FC4A43A-448C-46C4-B1F1-5A84192F42FDQ38791566-E447AF3F-45FF-4597-AE8D-C990F0792E5EQ38840953-F567F2CB-3075-4FDE-A3F1-4FDAB0231A8FQ38945176-21678E7A-9908-4252-AACC-86289541AF06Q39077715-F0538D1D-1EB6-40B9-961D-D346A0B208CBQ39391672-DE356A30-9443-41B4-8C71-2C318C42C148Q40055374-812588AC-AE74-4FCD-97FE-39433E5F3BF4Q42773009-54B86FCE-F403-4DDE-9F3A-DE51C1828769Q47555157-2D02D4EA-21C4-4C1E-B9F9-0319E1E42C4EQ47594518-652475CA-DE84-4916-AEEB-8089B1DABC2DQ55040035-279E83BA-AE4D-42F2-92E4-AE9D5F2B9676Q55142706-F235EF8C-EA51-42E4-95E3-0901ECBD3975Q55505691-151D2AD2-983B-4FC9-B7CD-91CF20BC34E9Q58778229-A3B9A014-946C-48B9-B78D-40F285316F63
P2860
Ondansetron in pregnancy and risk of adverse fetal outcomes.
description
2013 nî lūn-bûn
@nan
2013 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Ondansetron in pregnancy and risk of adverse fetal outcomes.
@ast
Ondansetron in pregnancy and risk of adverse fetal outcomes.
@en
Ondansetron in pregnancy and risk of adverse fetal outcomes.
@nl
type
label
Ondansetron in pregnancy and risk of adverse fetal outcomes.
@ast
Ondansetron in pregnancy and risk of adverse fetal outcomes.
@en
Ondansetron in pregnancy and risk of adverse fetal outcomes.
@nl
prefLabel
Ondansetron in pregnancy and risk of adverse fetal outcomes.
@ast
Ondansetron in pregnancy and risk of adverse fetal outcomes.
@en
Ondansetron in pregnancy and risk of adverse fetal outcomes.
@nl
P356
P1476
Ondansetron in pregnancy and risk of adverse fetal outcomes.
@en
P2093
Henrik Svanström
P304
P356
10.1056/NEJMOA1211035
P407
P577
2013-02-01T00:00:00Z